Shaker R Dakhil, MD | |
818 N Emporia St, Suite 403, Wichita, KS 67214-3729 | |
(316) 262-4467 | |
(316) 262-0706 |
Full Name | Shaker R Dakhil |
---|---|
Gender | Male |
Speciality | Hematology/oncology |
Experience | 49 Years |
Location | 818 N Emporia St, Wichita, Kansas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1417918079 | NPI | - | NPPES |
1286700005 | Other | KS | DMERC REGION 1 |
1286700012 | Other | KS | DMERC REGION 1 |
1286700015 | Other | KS | DMERC REGION 1 |
100189840A | Medicaid | KS | |
1286700002 | Other | KS | DMERC REGION 1 |
1286700003 | Other | KS | DMERC REGION 1 |
1286700008 | Other | KS | DMERC REGION 1 |
900000947 | Other | KS | RAILROAD MEDICARE |
1286700009 | Other | KS | DMERC REGION 1 |
1286700011 | Other | KS | DMERC REGION 1 |
1286700013 | Other | KS | DMERC REGION 1 |
12867010010 | Other | KS | DMERC REGION 1 |
1286700004 | Other | KS | DMERC REGION 1 |
1286700007 | Other | KS | DMERC REGION 1 |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RH0003X | Internal Medicine - Hematology & Oncology | 0418826 (Kansas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
William Newton Hospital | Winfield, KS | Hospital |
Wesley Medical Center | Wichita, KS | Hospital |
Via Christi Hospital-wichita | Wichita, KS | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Cancer Center Of Kansas Pa | 5395732820 | 23 |
News Archive
University of Delaware scientists have invented a novel biomaterial with surprising antibacterial properties that can be injected as a low-viscosity gel into a wound where it rigidifies nearly on contact-opening the door to the possibility of delivering a targeted payload of cells and antibiotics to repair the damaged tissue.
Frontiers in Clinical Drug Research - Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases - diabetes and obesity.
CEL-SCI Corporation. (NYSE Amex: CVM), a biotechnology company entering a late stage oncology trial and focused on infectious disease, today announced that it has entered into a definitive agreement with several institutional investors to sell 9.7 million units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $4.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.
A new study finds that brachytherapy, a common procedure that delivers radiation directly to cancer cells, may continue safely, potentially without delay or antibiotics, in cervical cancer patients following uterine perforation.
› Verified 6 days ago
Entity Name | Cancer Center Of Kansas Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1841251394 PECOS PAC ID: 5395732820 Enrollment ID: O20040427001505 |
News Archive
University of Delaware scientists have invented a novel biomaterial with surprising antibacterial properties that can be injected as a low-viscosity gel into a wound where it rigidifies nearly on contact-opening the door to the possibility of delivering a targeted payload of cells and antibiotics to repair the damaged tissue.
Frontiers in Clinical Drug Research - Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases - diabetes and obesity.
CEL-SCI Corporation. (NYSE Amex: CVM), a biotechnology company entering a late stage oncology trial and focused on infectious disease, today announced that it has entered into a definitive agreement with several institutional investors to sell 9.7 million units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $4.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.
A new study finds that brachytherapy, a common procedure that delivers radiation directly to cancer cells, may continue safely, potentially without delay or antibiotics, in cervical cancer patients following uterine perforation.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Shaker R Dakhil, MD 818 N Emporia St, Suite 403, Wichita, KS 67214-3729 Ph: (316) 262-4467 | Shaker R Dakhil, MD 818 N Emporia St, Suite 403, Wichita, KS 67214-3729 Ph: (316) 262-4467 |
News Archive
University of Delaware scientists have invented a novel biomaterial with surprising antibacterial properties that can be injected as a low-viscosity gel into a wound where it rigidifies nearly on contact-opening the door to the possibility of delivering a targeted payload of cells and antibiotics to repair the damaged tissue.
Frontiers in Clinical Drug Research - Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases - diabetes and obesity.
CEL-SCI Corporation. (NYSE Amex: CVM), a biotechnology company entering a late stage oncology trial and focused on infectious disease, today announced that it has entered into a definitive agreement with several institutional investors to sell 9.7 million units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $4.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.
A new study finds that brachytherapy, a common procedure that delivers radiation directly to cancer cells, may continue safely, potentially without delay or antibiotics, in cervical cancer patients following uterine perforation.
› Verified 6 days ago
Ahmad Qaddour, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9300 E 29th St N, Suite 310, Wichita, KS 67226 Phone: 316-858-9000 Fax: 316-858-9005 | |
Kathryn Watkins Brickman, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 550 N Hillside St, Wichita, KS 67214 Phone: 316-962-2000 Fax: 303-306-7753 | |
Ray F Fisher, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 818 N Carriage Pkwy, Wichita, KS 67208 Phone: 316-651-2252 Fax: 316-651-2314 | |
Mitchell A Morgan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1131 S Clifton Ave, Suite B, Wichita, KS 67218 Phone: 316-462-1040 Fax: 316-462-1042 | |
Dr. Kent B Murray, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 5500 E Kellogg Dr, Wichita, KS 67218 Phone: 316-651-3603 Fax: 316-651-6666 | |
Dr. Raghu C Chaparala, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2160 W 21st St N, Wichita, KS 67203 Phone: 316-267-7175 Fax: 316-425-7799 | |
Layne M Reusser, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9350 E 35th St N, Ste 101, Wichita, KS 67226 Phone: 316-265-1308 Fax: 316-712-9286 |